The primary goal of many DIA based experiments is to discover proteins or peptides (candidates) that are differentially expressed in two or more conditions. Improvements in DIA workflow are typically measured based on identification, precision, and accuracy.

Presenter: Sira Echevarria

Date: Wednesday, Sep 20, 2023, 11:45 AM – 1:00 PM
Session: PP05

This poster, presented at US HUPO 2024, presents directDIA+ performance for dia-PASEF projects in Spectronaut compared with DIA-NN 1.8.1 in terms of identification and ability to detect true candidates in controlled quantitative experiments.

Poster ThP MS2 presented at ASMS 2022

Presenter: Oliver Bernhardt
Session: Informatics: Algorithms and Statistical Advances
Date: Thursday, June 9

Presenter: Roland Bruderer

Date: Monday, June 5
Topic area: Biomarkers: Quantitative Analysis I

Presenter: Monika Pepelnjak

Date: Tuesday, June 6
Topic area: Drug Discovery: Qualitative and Quantitative Analysis II

Poster presented at IMSC 2022

 
Presenter: Sira Echevarria-Zomeno

Session: Poster Session B
Date: August 31 and September 1

The fusion of trapped ion mobility spectrometry (TIMS) with parallel reaction monitoring (PRM), particularly through the prm-PASEF ® technique, is indeed a groundbreaking development in proteomics. This innovative approach leverages the parallel accumulation-serial fragmentation (PASEF) mode to synchronize ion release from TIMS with selective precursor isolation, reducing the noise in the peptide ion spectra without sacrificing sensitivity.

Numerous software tools, including Spectronaut, have been developed to interpret the increasingly complex and voluminous raw data generated from mass-spectrometry-based proteomics data. These resulting datasets are typically extensive and challenging to analyze, necessitating substantial expertise in the field of proteomics.

While aging remains the most significant risk factor for neurodegenerative diseases (NDs) such as Alzheimer’s disease (AD) or Parkinson’s disease (PD), the biological pathways that are altered in healthy aging vs. pathologic aging leading to neurodegeneration remain to be elucidated. Since the genome remains invariant throughout the lifespan, it is essential to understand the effects of aging on the proteome as proteins play an integral role in all cellular functions and mediate the effects of epigenetic alterations. In addition, while the brain remains protected by the blood-brain barrier, there is increasing evidence that events such as systemic inflammation, metabolic dysfunction significantly affect the risk for the development of various NDs.

New: Spectronaut^® 19

Unlock Your Data's True Story

New: Spectronaut^® 19

Unlock Your Data's True Story

Learn More